Clinical Trial Update: Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 study of IHL-675A in rheumatoid arthritis was terminated. The update reports safety and effects on pain and function as measured by RAPID-3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• IHL-675A

Snippet

Sponsor: Incannex Healthcare Ltd | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED